On January 23rd, Maxvax announced the successful enrollment and vaccination of all subjects in the Phase II clinical trial for its recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) at the Disease Control and Prevention Center in Liangyuan District, Shangqiu City, Henan Province. This marks the first domestic RSV vaccine to enter Phase II clinical trials in China.
more >On November 10, 2024, the kick-off meeting of the Phase I/II clinical trial of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) independently developed by Maxvax was held in China’s Henan Province, and the enrollment of the first subjects was completed on the same day, marking the official start of the clinical trial of this vaccine candidate.
more >Maxvax's innovative novel adjuvant team has successfully published a landmark research article in one of the world’s most prestigious scientific journals, Angewandte Chemie International Edition (Impact Factor 16.1).
more >On July 13, 2024, Maxvax’s recombinant herpes zoster (Shingles) vaccine (CHO cell) finished the enrollment of its first human subject for Phase III clinical trial in China’s Henan Province, marking the launch of the vaccine’s Phase III clinical trial.
more >Chengdu Maxvax Biotechnology LLC (Maxvax) announced the completion of a 200-million-yuan convertible bond financing on the day following New Year’s Day, with investment from Shenzhen Capital Group’s (SCGC) National New Materials Fund for Manufacturing Transformation and Upgrading.
more >Chengdu Maxvax Biotechnology LLC. recently announced the completion of its Series C+ financing round, raising over 300 million CNY.
more >
On January 23rd, Maxvax announced the successful enrollment and vaccination of all subjects in the Phase II clinical trial for its recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) at the Disease Control and Prevention Center in Liangyuan District, Shangqiu City, Henan Province. This marks the first domestic RSV vaccine to enter Phase II clinical trials in China.
more >
Maxvax's innovative novel adjuvant team has successfully published a landmark research article in one of the world’s most prestigious scientific journals, Angewandte Chemie International Edition (Impact Factor 16.1).
more >
Chengdu Maxvax Biotechnology LLC (Maxvax) announced the completion of a 200-million-yuan convertible bond financing on the day following New Year’s Day, with investment from Shenzhen Capital Group’s (SCGC) National New Materials Fund for Manufacturing Transformation and Upgrading.
more >
On November 10, 2024, the kick-off meeting of the Phase I/II clinical trial of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) independently developed by Maxvax was held in China’s Henan Province, and the enrollment of the first subjects was completed on the same day, marking the official start of the clinical trial of this vaccine candidate.
more >
On July 13, 2024, Maxvax’s recombinant herpes zoster (Shingles) vaccine (CHO cell) finished the enrollment of its first human subject for Phase III clinical trial in China’s Henan Province, marking the launch of the vaccine’s Phase III clinical trial.
more >
Chengdu Maxvax Biotechnology LLC. recently announced the completion of its Series C+ financing round, raising over 300 million CNY.
more >